Tag: PXT3003
Pharnext advances analysis of data from the pivotal Phase III study of PXT3003 in Charcot-Marie-Tooth disease type 1A
By Hector Chaunu Published on 02/28/2024 at 9:00 a.m. Photo credit © ChaunuPictures (Boursier.com) — Pharnext SCA,…
The fate of Pharnext suspended on the PXT3003 trial carried out in China
(AOF) – Pharnext announces that in accordance with its commitment dated January 17, it has stopped all its operational expenses, the time to complete the additional analyzes of the Premier…
PHARNEXT: Pharnext announces its intention to prepare registration and marketing authorization files for PXT3003, its drug candidate in Charcot-Marie-Tooth disease type 1A – 12/19/2023 at 08:00: 00
PARIS, France, December 19, 2023 at 8:30 a.m. (CET) – Pharnext SCA (FR001400JXB0 – ALPHA) (the “Company”), an advanced clinical stage biopharmaceutical company developing new therapies for neurodegenerative diseases without…
Pharnext has successfully manufactured its PXT3003 product in the United States – 11/20/2023 at 10:10 a.m.
(AOF) – Pharnext announces that it has successfully manufactured registration batches of PXT3003 in the United States. The biotech developing new therapies for neurodegenerative diseases specifies that this success was…
Pharnext widens its losses in the first half of 2022 but advances on the PXT3003 – 10/17/2022 at 11:22
(AOF) – Pharnext, a biopharmaceutical company at an advanced clinical stage, posted a net loss of 19.10 million euros in the first half of 2022 against 13.55 million at the…
Pharnext signs a financing agreement with Néovacs for a net amount of 20.7 million euros allowing the continuation of the development of PXT3003 in Charcot-Marie-Tooth disease type 1A – 10/03/2022 at 18:00
• At the end of this financing program, carried out via the issue in several tranches of simple bonds for a total nominal amount of approximately 21 million euros (i.e.…
Pharnext announces the inclusion of the first patient in the open label extension of the pivotal Phase III study of PXT3003 in Charcot-Marie-Tooth disease type 1A, the PREMIER trial – 09/12/2022 at 08: 30
PARIS, France, September 12, 2022 at 8:30 a.m. (CET) – Pharnext SA (FR0011191287 – ALPHA) (“the Company”), an advanced clinical-stage biopharmaceutical company developing new therapies for neurodegenerative diseases with no…
Pharnext Announces Enrollment of the First Patient in the Open-Label Extension of the Pivotal Phase III Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A, the PREMIER Trial
Pharnext Announces Enrollment of the First Patient in the Open-Label Extension of the Pivotal Phase III Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A, the PREMIER Trial PARIS, France, September…
Neovacs plans to invest in Pharnext to fund the pivotal phase III study of PXT3003 in Charcot’s disease
By Claude Leguilloux Published on 08/08/2022 at 08:07 Photo credit © Reuters (Boursier.com)…
NEOVACS: NEOVACS PLANS TO INVEST IN PHARNEXT TO FUND PIVOT PHASE III CLINICAL STUDY OF PXT3003 IN CHARCOT-MARIE-TOOTH DISEASE TYPE 1A – 08/08/2022 at 08:00
Paris, August 8, 2022 – 8 a.m. CET – Neovacs (Euronext Growth Paris: ALNEV) announces that it has entered into negotiations with the company Pharnext (Euronext Growth Paris: ALPHA) in…